Jul 13, 2017
Over the past year, CancerLinQ LLC, a wholly owned nonprofit of ASCO, has announced several new collaborations with a variety of organizations in cancer care. This multidisciplinary coalition of leaders is committed to accelerating the ability to gather new insights from the CancerLinQ® platform. The expert guidance from these partners from the public, private, and not-for-profit sectors will help to improve quality, efficiency, and value for the entire cancer care continuum.
A new collaboration with the U.S. Food and Drug Administration (FDA) will harness cancer patient information and big data analytics to examine the real-world use of emerging and newly approved cancer therapies. CancerLinQ and FDA will collaborate to use data from CancerLinQ to grow the knowledge base about patterns of care across all cancer types and therapies, accelerate development of novel insights that might otherwise be challenging to obtain through standard research initiatives and data collection means, and inform FDA regulatory strategy and decision-making processes.
An additional effort will facilitate the exchange of information between CancerLinQ participating oncology practices and the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) program, the primary source of data on cancer incidence and survival in the United States. This collaboration aims to put valuable population-level cancer data at oncologists’ fingertips, while also strengthening the nation’s cancer surveillance efforts through a national data-sharing collaboration.
CancerLinQ has also announced official partnerships with a number of organizations, including the American Society of Radiation Oncology (ASTRO), American Academy of Physician Assistants (AAPA), College of American Pathologists (CAP), Cancer Informatics for Cancer Centers (CI4CC), Hematology/Oncology Pharmacy Association (HOPA), Society of Gynecologic Oncology (SGO), Oncology Nursing Society (ONS), and National Comprehensive Cancer Network (NCCN). In addition, AstraZeneca is the founding enterprise partner for CancerLinQ Discovery™, which launched in November 2016 and will provide curated, de-identified sets of clinical data for those interested in pursuing hypothesis-driven research. Together, these partnerships will help CancerLinQ achieve its vision of building strategic alliances to create a multidisciplinary coalition that learns from every patient to rapidly improve the quality of care for people with cancer.
Leaders from these groups will engage with the CancerLinQ Oncology Leadership Council and other CancerLinQ advisory groups. CancerLinQ believes that bringing together the best minds in the cancer community can strengthen the platform’s role as a go-to resource for the health care community and improve the lives of patients around the world for generations to come. For more information on the latest collaborations, visit
CancerLinQ is a powerful platform containing vast amounts of real-world cancer information. This national initiative will allow cancer providers to improve the quality and value of care by analyzing millions of cancer patient medical records, uncovering patterns and trends, and measuring their care against that of their peers and recommended guidelines.
CancerLinQ and CancerLinQ Discovery are projects of CancerLinQ LLC. Visit CancerLinQ for more information on how to participate or partner with CancerLinQ.